First chikungunya vaccine approved
European Pharmaceutical Review
NOVEMBER 10, 2023
The Phase III results were published in The Lancet in June 2023. In October 2023, Valneva submitted a marketing application for the chikungunya vaccine to the European Medicines Agency (EMA), which included initial safety data from the trial. IXCHIQ-induced seroresponse was sustained over time with a 96.3
Let's personalize your content